식도암으로 인한 식도 절제술 후 문합 누출을 예방하기 위한 관내 진공 치료 (ESPY)
식도암으로 인한 식도절제술 후 문합부 누출을 예방하기 위한 선제적 관내 진공 치료를 평가하기 위한 전향적, 다기관, 탐색적 및 관찰적 단일 연구
A prospective, multi-centre, exploratory and observational one-arm study to evaluate preventive Endoluminal Vacuum Therapy(pEVT) to prevent anastomotic leakage after esophagectomy due to esophageal cancer. The main objective is to evaluate the potential protective effect of prophylactic preemptive endoluminal vacuum therapy on esophageal-gastric anastomosis dehiscence after esophagectomy.
연구 개요
상세 설명
Prospective, multi-centre, exploratory and observational one-arm study to evaluate preemptive endoluminal vacuum therapy to prevent anastomotic leakage after esophagectomy due to esophageal cancer.
The study comprises a maximum of 5 visits per protocol. At visit 0, informed consent will be obtained, and the patient will be checked for compliance with all inclusion criteria and no exclusion criteria in the study. Demographic characteristics, medical history and oncological parameters will be collected. At visit 1 ttMILE will be carry out and immediately (0-24h) after completion of the anastomosis, in patients who meet selection criteria, the Eso-SPONGE® will be placed endoscopically via an overtube, as usual clinical practice of the centre. The tube will be routed transnasally and then connected to a vacuum pump, generating a continuous negative pressure of 75 mmHg. The Eso-SPONGE system will be checked 6-hourly for leakage and dislocation. The sponge will be removed after 4-6 days (V2). After removal, the anastomosis and the gastric tube will be assessed endoscopically to exclude leakage and evaluate ischemia and stenosis, and the pylorus will be evaluated for spasm. The next visits (V3 and V4) will be carried out at 30 and 90 days after the intervention has been placed. Leakage, ischemia and stenosis will be clinically evaluated at each visit and a new endoscopy will be performed in patient who show symptoms.
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
Catalonia
-
Barcelona, Catalonia, 스페인, 08036
- Hospital Clinic de Barcelona
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients undergoing a total minimally invasive (laparoscopic or robotic and thoracoscopic) transthoracic Ivor Lewis esophagectomy (ttMILE) due to esophageal cancer and subsequent eso-SPONGE® application to prevent anastomotic leakage (AL)
설명
Inclusion Criteria:
- Age ≥ 18 years
- Scheduled for total minimally invasive (laparoscopic or robotic and thoracoscopic) transthoracic Ivor Lewis esophagectomy (ttMILE) due to esophageal cancer and subsequent eso-SPONGE application to prevent anastomotic leakage
- Patients able to read and understand the Patient Information Sheet and sign, if accepted, the Informed Consent Form
- Patients able, at the discretion of the investigator, to comply with the requirements of the study and without impediments to follow the instructions and assessments throughout the study.
Exclusion Criteria:
- Patients undergoing transhiatal esophagectomy without reconstruction, open Ivor Lewis esophagectomy or other esophageal resections different to ttMILE.
- Multi-organ resection during the esophagectomy.
- Emergent-urgent esophagectomy.
- Coloplasty or small bowel plasty.
- Necrotic tissue/gangrene.
- Blood clotting disorder.
- Bleeding esophageal varices.
- Sponge placement required directly on major vessels.
- Patients with known sensitivities or allergies to its components
- Participation in any other clinical trial and use of any drug or experimental device, currently or in the 4 weeks prior to inclusion in the study.
- Women who are pregnant, suspected of being pregnant or breastfeeding.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Eso-SPONGE®
endoluminal vacuum therapy to prevent anastomotic leakage after esophagectomy due to esophageal cancer |
minimally invasive treatment and prevention of anastomotic leakages and perforations in the upper gastrointestinal tract (upper GIT)
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate of patients with anastomotic leakage
기간: throughout the duration of the study (until last follow-up at postoperative day 90)
|
Anastomotic leakage (AL) is a severe complication following gastric and esophageal surgery. Anastomotic leakage occurs in 5-30% of patients after esophagectomy and may be further complicated by mediastinitis, sepsis, multiple organ failure, or death. The primary objective of the study is to evaluate the potential protective effect of prophylactic preemptive endoluminal vacuum therapy on esophageal-gastric anastomosis dehiscence after esophagectomy. |
throughout the duration of the study (until last follow-up at postoperative day 90)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Comprehensive Complication Index
기간: Postoperative day 30 and day 90
|
The Comprehensive Complication Index (CCI®) calculates the overall morbidity of a patient after any surgical intervention based on the complication grading by the "Clavien-Dindo Classification" (CDC). The Comprehensive Complication Index (CCI®) reflects the gravity of this overall complication burden on the patient on a scale from 0 (no complication) to 100 (death). |
Postoperative day 30 and day 90
|
|
Description of Adverse Events
기간: throughout the duration of the study (until last follow-up at postoperative day 90)
|
All the Adverse Events reported during the study will be described together with their characteristics, noting those related with the investigational device application. |
throughout the duration of the study (until last follow-up at postoperative day 90)
|
|
Rate of postoperative ischemia
기간: Postoperative day 30 and day 90
|
The different grades of postoperative ischemia at Visit 1, Visit 2 and Visit 3 |
Postoperative day 30 and day 90
|
|
Rate of postoperative mortality
기간: Postoperative day 30 and day 90
|
The percentage of patients who died along the study will be described in terms of absolute and relative frequencies, as well as causes for death and time until death regarding investigational device application. |
Postoperative day 30 and day 90
|
|
Rate of postoperative stenosis
기간: throughout the duration of the study (until last follow-up at postoperative day 90)
|
The percentage of postoperative stenosis at Visit 1, Visit 2 and Visit 3, as well as along the study |
throughout the duration of the study (until last follow-up at postoperative day 90)
|
|
Length of hospitalization
기간: until discharge (approximately 10 days postoperatively)
|
time elapsed until reaching the "fit for discharge criteria" regarding investigational device application |
until discharge (approximately 10 days postoperatively)
|
|
Re-admissions to hospital
기간: throughout the duration of the study (until last follow-up at postoperative day 90)
|
The percentage of patients re-admitted along the study will be described; as well as the time elapsed until re-admission regarding investigational device application |
throughout the duration of the study (until last follow-up at postoperative day 90)
|
|
Surgical reoperations
기간: throughout the duration of the study (until last follow-up at postoperative day 90)
|
The percentage of patients with surgical reoperations along the study will be described; as well as the time elapsed until surgical reoperation regarding investigational device application |
throughout the duration of the study (until last follow-up at postoperative day 90)
|
|
Anastomotic leakage free survival
기간: throughout the duration of the study (until last follow-up at postoperative day 90)
|
Event free survival at 30 days and at 90 days will be analyzed using Kaplan-Meier method, considering the anastomotic leakage reported during the study. Patients with no anastomotic leakage during the analyzed period will be censored at last follow-up date |
throughout the duration of the study (until last follow-up at postoperative day 90)
|
|
Rate of intraluminal hemorrhage
기간: throughout the duration of the study (until last follow-up at postoperative day 90)
|
The percentage of patients with intraluminal hemorrhage along the study will be described in terms of absolute and relative frequencies; as well as the time elapsed until hemorrhage regarding investigational device application. Additionally, to see the distribution of the time until intraluminal hemorrhage Kaplan-Meier method will be performed at 90 days (patients with no intraluminal hemorrhage during the study will be censored at last follow-up date). |
throughout the duration of the study (until last follow-up at postoperative day 90)
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Dulce Momblán García, Dr., Hospital Clinic of Barcelona
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- AAG-O-H-2209
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .